Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ticagrelor-based antiplatelet regimens during primary PCI for STEMI
ChiCTR-IPR-14005315Phase 4Recruiting
- Sponsor
- Guangdong Kanghua Healthcare Group
- Start
- Sep 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of ticagrelor, clopidogrel, heparin, bivalirudin and aspirin in acute ST-segment elevation myocardial infarction (STEMI) (3 arms), sponsored by Guangdong Kanghua Healthcare Group. Primary endpoints: Electrocardiogram, Serum troponin T and 8 more. Started Sep 2014; status: recruiting.
02
Drugs
ticagrelorclopidogrelheparinbivalirudinaspirin
03
Conditions
acute ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on ChiCTR-IPR-14005315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-14005315.